Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency
改善雄激素缺乏的前列腺癌幸存者的生活质量
基本信息
- 批准号:9750591
- 负责人:
- 金额:$ 75.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse eventAdvocateAerobicAffectAffectiveAmericanAndrogensAreaAttentionBiochemicalCancer SurvivorCardiovascular systemClinical Trials Data Monitoring CommitteesComplexDataDiagnosisDiseaseDistressDouble-Blind MethodElementsEnrollmentEquilibriumEvaluationFatigueFrightFunctional disorderGelGene ExpressionGleason Grade for Prostate CancerGrowthHematocrit procedureHigh PrevalenceLettersLipidsLocalized DiseaseMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetastatic Prostate CancerMonitorMoodsOncologistOncology GroupOrganParticipantPatient Self-ReportPatientsPerformancePersonal SatisfactionPhysical FunctionPlacebosPopulationProstateProstate specific antigen measurementPublished CommentQuality of lifeRadical ProstatectomyRandomizedRecommendationRecurrenceReportingResearchRiskSafetySex BehaviorSex FunctioningSexual DysfunctionSpecific qualifier valueStructureSubjects SelectionsSurvivorsSymptomsTestosteroneUrologistVO2maxandrogen sensitivebasedeprivationdisorder riskeditorialefficacy trialepidemiology studyfeasibility trialhealth related quality of lifeimprovedinstrumentlean body massmenmultidisciplinarymuscle formmuscle strengthopen labelpatient populationprostate cancer riskrandomized trialrisk minimizationsurvivorshipsymptom treatmentsymptomatic improvementtestosterone replacement therapytrial design
项目摘要
SUMMARY
Substantial improvement in survival in men with prostate cancer (PCa) has focused attention on the high
prevalence of sexual dysfunction, physical dysfunction, and low energy, which are important contributors to
suboptimal health-related quality of life (HRQOL) in prostate cancer survivors. The pathophysiology of these
symptoms in prostate cancer survivors is multifactorial, but androgen deficiency is a frequent, remediable
contributor. In healthy hypogonadal men, testosterone replacement therapy (TRT) improves these symptoms,
suggesting that it also might do so for survivors of PCa who have testosterone deficiency. However, because
testosterone promotes the growth of metastatic prostate cancer, there has been concern about administering
TRT to prostate cancer survivors. Open label trials and retrospective analyses have reported very low
recurrence rates in men who have undergone radical prostatectomy and received TRT, but neither safety nor
efficacy have been evaluated in a randomized trial in this population. The South West Oncology Group patient
advocates have deemed this a high priority question for prostate cancer survivors.
Our primary aim is to conduct a double-blind, placebo-controlled, parallel-group, randomized trial to determine
whether testosterone replacement is safe and efficacious in improving sexual function in men with androgen
deficiency, who have undergone radical prostatectomy for pT2,N0,M0, Gleason score ≤6 disease and are at
very low risk of disease recurrence. A secondary aim is to determine whether TRT improves muscle mass and
strength, and self reported and performance-based measures of physical function. The third objective is to
determine the effects of TRT on wellbeing and affect, mood, energy, and quality of life. The trial will enroll men,
40 years or older, who have undergone radical prostatectomy for organ-localized prostate cancer (pT2,N0,M0);
with Gleason score ≤6; pre-treatment PSA <10 ng/mL; and undetectable PSA (<0.1 ng/mL) for at least two
years after radical prostatectomy; who have symptoms of sexual dysfunction, fatigue, or physical dysfunction;
and who have unequivocally low total (average of two morning levels <275 ng/dL) or free testosterone (<60
pg/mL) levels. Participants will be randomized to receive placebo or testosterone gel for 12 weeks. Changes in
sexual activity, sexual desire, erectile function, sexual distress, sexual life quality, lean body mass, muscle
strength, physical function, affectivity balance, and energy will be evaluated at baseline, 6 and 12 weeks. We
will monitor hematocrit, PSA, and biochemical recurrence, defined as” PSA of ≥0.2 ng/mL with a confirmatory
level of ≥0.2 ng/mL”. Careful selection of subjects with very low risk of recurrence, rigorous safety monitoring,
pre-specified stopping rules, and oversight by an independent DSMB will minimize risks. Extensive preliminary
data support the feasibility of this trial. Randomized trial design, a multidisciplinary team, careful attention to
statistical power, and selection of symptomatic men with unequivocally low testosterone will insure the validity
of the assessment of efficacy and safety of testosterone therapy in this needy patient population.
总结
男性前列腺癌(PCa)患者生存率的显著改善将注意力集中在高水平的
性功能障碍、身体功能障碍和精力低下的患病率,这些都是导致
前列腺癌幸存者的次优健康相关生活质量(HRQOL)。这些疾病的病理生理学
前列腺癌幸存者的症状是多因素的,但雄激素缺乏是一种常见的,可治愈的
贡献者。在健康的性腺功能减退男性中,睾酮替代疗法(TRT)可改善这些症状,
这表明它也可能对患有睾丸激素缺乏症的PCa幸存者起作用。但由于
睾丸激素促进转移性前列腺癌的生长,
TRT治疗前列腺癌幸存者。开放标签试验和回顾性分析报告了非常低的
接受根治性直肠癌切除术并接受TRT的男性的复发率,但安全性和
在该人群中的随机试验中评价了疗效。西南肿瘤组的病人
倡导者认为这是前列腺癌幸存者的一个高度优先的问题。
我们的主要目的是进行一项双盲、安慰剂对照、平行组、随机试验,以确定
睾酮替代治疗在改善雄激素男性性功能方面是否安全有效
缺乏症,因pT 2、N 0、M0、Gleason评分≤6分的疾病接受根治性乳腺癌切除术,
疾病复发的风险非常低。第二个目的是确定TRT是否改善肌肉质量,
力量,自我报告和基于表现的身体功能测量。第三个目标是
确定TRT对健康和情感,情绪,能量和生活质量的影响。试验将招募男性,
40岁或以上,因器官局限性前列腺癌(pT 2,N 0,M0)接受根治性前列腺切除术;
Gleason评分≤6;治疗前PSA <10 ng/mL;和至少两种情况下检测不到PSA(<0.1 ng/mL)
根治性前列腺切除术后3年;有性功能障碍、疲劳或身体功能障碍症状的患者;
和明确低总(两个早晨的平均水平<275 ng/dL)或游离睾酮(<60
pg/mL)水平。参与者将随机接受安慰剂或睾酮凝胶12周。变化
性活动,性欲,勃起功能,性困扰,性生活质量,瘦体重,肌肉
将在基线、第6周和第12周评价力量、身体功能、情感平衡和能量。我们
将监测红细胞压积、PSA和生化复发,定义为”PSA ≥0.2 ng/mL,
水平≥0.2 ng/mL”。仔细选择复发风险极低的受试者,严格的安全性监测,
预先规定的停止规则和独立DSMB的监督将最大限度地降低风险。广泛的初步
数据支持这项试验的可行性。随机试验设计,多学科团队,仔细关注
统计功效和选择有明显低睾酮症状的男性将确保有效性
评估睾酮治疗在这一需要帮助的患者人群中的有效性和安全性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHALENDER BHASIN其他文献
SHALENDER BHASIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHALENDER BHASIN', 18)}}的其他基金
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
- 批准号:
10430705 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
- 批准号:
10668324 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
- 批准号:
10311161 - 财政年份:2021
- 资助金额:
$ 75.47万 - 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
- 批准号:
10457489 - 财政年份:2021
- 资助金额:
$ 75.47万 - 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
- 批准号:
10634622 - 财政年份:2021
- 资助金额:
$ 75.47万 - 项目类别:
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency
改善雄激素缺乏的前列腺癌幸存者的生活质量
- 批准号:
10398005 - 财政年份:2018
- 资助金额:
$ 75.47万 - 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
- 批准号:
9767249 - 财政年份:2018
- 资助金额:
$ 75.47万 - 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
- 批准号:
10159744 - 财政年份:2018
- 资助金额:
$ 75.47万 - 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
- 批准号:
10398790 - 财政年份:2018
- 资助金额:
$ 75.47万 - 项目类别:
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency
改善雄激素缺乏的前列腺癌幸存者的生活质量
- 批准号:
9918241 - 财政年份:2018
- 资助金额:
$ 75.47万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 75.47万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 75.47万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 75.47万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 75.47万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 75.47万 - 项目类别: